BioVaxys Reports Positive Phase 1B/2 Results for MVP-S Combo in Recurrent Ovarian Cancer
I'm PortAI, I can summarize articles.
BioVaxys Technology Corp. has reported positive preliminary results from its Phase 1B/2 PESCO clinical trial for the MVP-S vaccine combined with pembrolizumab and low-dose cyclophosphamide in recurrent ovarian cancer patients. The trial, led by Dr. Amit Oza, evaluated safety, dosing, and clinical efficacy, showing promising outcomes, particularly in platinum-resistant cases. Notably, one subject has maintained a complete response for three years. The results have been presented, highlighting improved efficacy over standard chemotherapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments